ALVAC-HIV (vCP1521)
AXP000202.1 · Vaccine
- Platform
- canarypox (ALVAC)
- Targets
- HIV-1 CRF01_AE gp120; HIV-1 Gag; HIV-1 protease
- Originator
- Virogenetics / Aventis Pasteur
- Sponsor
- Sanofi Pasteur
Names
Virus
- Role
- Vaccine vector
- Family
- Poxviridae
- Virus
- canarypox virus (NCBI Taxonomy 44088)
- Strain
- ALVAC (vCP1521)
- Replication
- non replicating
- Modifications
- HIV-1 CRF01_AE (92TH023) env gp120 with clade B LAI gp41 anchor, plus LAI gag and protease
- Transgenes
- HIV-1 env gp120 (CRF01_AE 92TH023), HIV-1 gag (LAI), HIV-1 protease (LAI)
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (4)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT02109354 | Safety of and Immune Response to Vaccination With 2 Experimental HIV Vaccines in Healthy Adults | Completed | Phase 1 | 2013-06-18 | 2015-02-02 | 202 | HIV Infection |
| NCT01435135 | Study of Late Boost Strategies for HIV-uninfected Participants From Protocol RV 144 | Unknown | Phase 2 | 2012-04 | 2021-07 | 162 | HIV Infections |
| NCT00223080 | HIV Vaccine Trial in Thai Adults | Completed | Phase 3 | 2003-10 | 2006-07 | 16402 | HIV Infection |
| NCT00098163 | Safety of and Immune Response to an HIV-1 Vaccine (ALVAC-HIV vCP1521) in Infants Born to HIV Infected Mothers | Completed | Phase 1 | 60 | HIV Infections |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40190112 | A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials. | Emerging microbes & infections | 2025 | cited by trial NCT00223080 |
| PMID 37256916 | Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response. | PLoS pathogens | 2023 | cited by trial NCT00223080 |
| PMID 31999736 | Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans. | PloS one | 2020 | cited by trial NCT00223080 |
| PMID 32035516 | Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial. | The lancet. HIV | 2020 | name in abstract: ALVAC-HIV vCP1521 |
| PMID 29702672 | Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations. | PloS one | 2018 | cited by trial NCT00223080 |
| PMID 28131393 | Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials. | Vaccine | 2017 | cited by trial NCT00223080 |
| PMID 28235027 | Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. | PLoS pathogens | 2017 | cited by trial NCT01435135 |
| PMID 28329190 | Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial. | The Journal of infectious diseases | 2017 | cited by trial NCT01435135 |
| PMID 26234467 | IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens. | AIDS research and human retroviruses | 2015 | name in abstract: ALVAC-HIV vCP1521 |
| PMID 24091694 | Immunogenicity of ALVAC-HIV vCP1521 in infants of HIV-1-infected women in Uganda (HPTN 027): the first pediatric HIV vaccine trial in Africa. | Journal of acquired immune deficiency syndromes (1999) | 2014 | cited by trial NCT00098163 |
| PMID 24504509 | Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. | PloS one | 2014 | cited by trial NCT00223080 |
| PMID 24829343 | Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial. | Journal of virology | 2014 | cited by trial NCT00223080 |
| PMID 25350851 | CD8 and CD4 epitope predictions in RV144: no strong evidence of a T-cell driven sieve effect in HIV-1 breakthrough sequences from trial participants. | PloS one | 2014 | cited by trial NCT00223080 |
| PMID 25401780 | Uptake of genital mucosal sampling in HVTN 097, a phase 1b HIV vaccine trial in South Africa. | PloS one | 2014 | cited by trial NCT02109354 |
| PMID 23221981 | Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in Uganda: results from the first HIV vaccine trial in infants in Africa. | Journal of acquired immune deficiency syndromes (1999) | 2013 | cited by trial NCT00098163 |
| PMID 22529301 | The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. | Journal of immunology (Baltimore, Md. : 1950) | 2012 | name in abstract: ALVAC-HIV vCP1521 |
| PMID 22634875 | Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. | The Journal of infectious diseases | 2012 | name in abstract: vCP1521 |
| PMID 22652344 | Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. | The Lancet. Infectious diseases | 2012 | name in title: ALVAC-HIV vCP1521 |
| PMID 23035746 | The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. | AIDS research and human retroviruses | 2012 | name in abstract: ALVAC-HIV vCP1521 |
| PMID 22205930 | Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand. | PloS one | 2011 | cited by trial NCT00223080 |
| PMID 19843557 | Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. | The New England journal of medicine | 2009 | cited by trial NCT00223080 |
| PMID 17909315 | A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. | Journal of acquired immune deficiency syndromes (1999) | 2007 | name in title: ALVAC-HIV vCP1521 |
| PMID 16910837 | Molecular epidemiology of HIV Type 1 in preparation for a Phase III prime-boost vaccine trial in Thailand and a new approach to HIV Type 1 genotyping. | AIDS research and human retroviruses | 2006 | name in abstract: ALVAC-HIV vCP1521 |
| PMID 15752839 | Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. | Vaccine | 2005 | name in abstract: ALVAC-HIV vCP1521 |
| PMID 15242541 | Enhanced sensitivity of detection of cytotoxic T lymphocyte responses to HIV type 1 proteins using an extended in vitro stimulation period for measuring effector function in volunteers enrolled in an ALVAC-HIV phase I/II prime boost vaccine trial in Thailand. | AIDS research and human retroviruses | 2004 | name in abstract: ALVAC-HIV vCP1521 |
| PMID 15272397 | Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. | The Journal of infectious diseases | 2004 | name in abstract: ALVAC-HIV vCP1521 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 31566582 | Simplified steps to heterologous prime-boost HIV vaccine development? | The Journal of clinical investigation | 2019 | name in abstract: vCP1521 |
| PMID 28645240 | Engineered Expression of Broadly Neutralizing Antibodies Against Human Immunodeficiency Virus. | Annual review of virology | 2017 | name in abstract: ALVAC-HIV vCP1521 |
| PMID 28678869 | V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. | PloS one | 2017 | name in abstract: vCP1521 |
| PMID 26041302 | Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates. | Journal of virology | 2015 | name in abstract: vCP1521 |
| PMID 24648341 | Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. | Science translational medicine | 2014 | name in abstract: ALVAC-HIV vCP1521 |
| PMID 22992109 | Short communication: evaluating the level of expressed HIV type 1 gp120 and gag proteins in the vCP1521 vector by two immunoplaque methods. | AIDS research and human retroviruses | 2013 | name in title: vCP1521 |
| PMID 23209178 | Human immunodeficiency virus vaccine trials. | Cold Spring Harbor perspectives in medicine | 2012 | name in abstract: ALVAC-HIV vCP1521 |
| PMID 20711452 | Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies. | PloS one | 2010 | name in abstract: vCP1521 |
| PMID 12757073 | Evaluation of attitude, risk behavior and expectations among Thai participants in Phase I/II HIV/AIDS vaccine trials. | Journal of the Medical Association of Thailand = Chotmaihet thangphaet | 2003 | name in abstract: ALVAC-HIV vCP1521 |
| PMID 12848591 | HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen. | Drugs in R&D | 2003 | name in abstract: ALVAC-HIV vCP1521 |
| PMID 11495295 | Cytotoxic T lymphocyte responses to vaccinia virus antigens but not HIV-1 subtype E envelope protein seen in HIV-1 seronegative Thais. | Asian Pacific journal of allergy and immunology | 2001 | name in abstract: vCP1521 |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| U19AI109646 | Cellular Responses | WISTAR INSTITUTE | WEINER, DAVID B. | 2015–2019 | name in abstract: vCP1521 |
| R01AI091450 | Modulation of HIV-specific CD8+ T and B cell function by CD4+ T helper responses | HENRY M. JACKSON FDN FOR THE ADV MIL/MED | STREECK, HENDRIK | 2010–2013 | name in abstract: ALVAC-HIV vCP1521 |
| R21AI096949 | T-follicular helper cells in Env-immunized macaques | UNIVERSITY OF MARYLAND BALTIMORE | PAUZA, C. DAVID | 2012–2013 | name in abstract: vCP1521 |
Notes
Canarypox vector vCP1521 carrying HIV-1 clade AE (92TH023) env gp120 anchored by a clade B LAI gp41 segment, plus clade B LAI gag and protease. Prime in the phase 3 RV144 trial in Thailand (>16,000 volunteers, US Army/Thai MoPH), boosted with the AIDSVAX B/E protein: 31.2% efficacy in the modified intent-to-treat analysis, reported 2009. The protein boost is a separate, non-viral product. Route (intramuscular) not confirmed from the pages opened.
How to cite
ALVAC-HIV (vCP1521) (AXP000202.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000202.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.